Building Better Payer Relationships in 2016: Three New Year’s Resolutions for Pharmaceutical Companies

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

It’s January, so right now it feels like everyone around us has made resolutions to get more exercise, eat better, or otherwise improve their lives. In that spirit, let’s take a look at what companies can do to improve their payer relationships in 2016. According to The Wall Street Journal, drug prices are on the rise, so the value propositions of health economics groups will be increasingly important when working with payers. Continue reading



Understanding the Potential Impact of Comparative Effectiveness Research in the US Payer Marketplace

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

The Institute for Clinical and Economic Review (ICER) announced in July that they are going to be producing reports on new drugs from a comparative effectiveness standpoint.  Quotes supporting ICER”s work from the Chief Medical Office of Express Scripts, Steve Miller MD, have raised questions within the industry about how the new influx of independent comparative effectiveness research will shape key decision-making processes on the payer side. Continue reading


Effectively Supporting Market Access with a Global Approach to Health Economics Research

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

In an increasingly competitive and cost-sensitive payer environment for pharmaceutical products, many market access and health economics groups are looking for ways to develop a comprehensive pharmacoeconomic message for new products as well as to support existing products.  As our research on these groups continues, one common thread that many successful groups share is a centralized health economics group that develops a broad set of data for country- or region-level groups to then localize and adapt to individual payers and/or PBMs. Continue reading


How Companies Decide on Patient-Reported Outcomes Delivery Mechanisms

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Patient-reported outcomes continue to be a growing interested for clinical trial sponsors.  To efficiently implement PRO instruments, companies must first determine which patient-reported outcomes delivery mechanisms best serve the trials.  For example, if an instrument is difficult to read, a patient may skip multiple sections.  If patients are asked to keep a paper diary, they may transcribe numbers incorrectly.  Or, if patients are asked to use digital technology—including iPads and other tablets—to report their information, some users may be unfamiliar with the technology or may experience some user error. Continue reading


Patient-Reported Outcomes Guidance: Looking to FDA to Drive Submissions

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As the patient voice becomes more important in healthcare, life sciences companies are increasingly looking to patient-reported outcomes as clinical trial endpoints.  While many pharmaceutical companies collect these endpoints for their emerging products, not all firms are sure of the requirements for turning these findings into product label claims.  The FDA has twice issued patient-reported outcomes guidance — once in 2006 and again in 2009 — to encourage adoption. Continue reading


Health Economics Spending: Prioritizing HEOR Activities at Global Groups

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Pharmaceutical companies under increasing pressure to provide a full product story to key payers.  As such, heath economics spending is also growing.  Rising stakeholder expectations demand that HEOR groups generate more pharmacoeconomic and outcomes data for each emerging drug or medical device.  To provide these data, global HEOR teams allocate a large percentage of their annual funding to cultivating  information for government and private payers worldwide. Continue reading


The Big Three: How Payers, Patients, and Physicians are Driving the Future of Comparative Effectiveness Research

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

Over the past few months at Cutting Edge Information we have been working on collecting data for a new report on comparative effectiveness research and a common theme throughout the research has been the need for stakeholder engagement that goes beyond the traditional payer-centric model.  Working with patients and physicians — along with pharmacies, regulators, and other stakeholders — is not a new phenomenon for manufacturers.  However, the emphasis on getting this engagement right is growing as companies respond to the changing healthcare marketplace in the US and in Europe. Continue reading


Balancing HEOR Team Priorities Between Short Term Approval Goals and Long Term Market Access Strategy

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

For many pharmaceutical companies, HEOR is a non-stop endeavor. Working to support existing products — while also developing value dossiers for products that are about to launch — can put a strain on available resources.  To a certain extent, the specifics of an HEOR team’s workload is dictated by market needs and external pressures.  But there are steps that can be taken internally to ensure that quality HEOR work is delivered on a consistent basis. Continue reading